SINTX Technologies, Inc. (SINT) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. SINTX Technologies is an advanced ceramics company specializing in medical-grade silicon nitride for biomedical and antipathogenic applications. The company is currently undergoing a strategic pivot away from low-margin OEM manufacturing toward the commercialization of proprietary medical devices. Notably, in October 2025 (subsequent to the period end), the company received FDA 510(k) clearance for its SiNAPTIC Foot & Ankle Osteotomy Wedge System.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $208,000 | $799,000 | $728,000 | $2,345,000 |
| Gross Profit | $93,000 | $589,000 | $273,000 | $1,688,000 |
| Net Loss | $(3,539,000) | $(6,239,000) | $(8,149,000) | $(9,329,000) |
| Net Loss Attributable to Common Stockholders | $(10,258,000) | $(6,239,000) | $(14,868,000) | $(9,329,000) |
| Cash and Cash Equivalents | $6,250,000 | $4,814,000 | $6,250,000 | $4,814,000 |
| Derivative Liabilities | $870,000 | $208,000 | $870,000 | $208,000 |
| Debt (Current) | $59,000 | $32,000 | $59,000 | $32,000 |
Note: All figures in thousands except per share data. Net loss attributable to common stockholders includes a $6.7 million deemed dividend related to a warrant inducement in Q3 2025.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 74% in Q3 2025 compared to Q3 2024. This is a strategic reduction of non-core, low-margin OEM contracts to focus on high-margin proprietary medical devices.
- Operating Expenses: Total operating expenses decreased 51% in Q3 2025 versus Q3 2024, primarily due to the absence of $4.5 million in "Armor exit costs" and $0.4 million in "reduction in force" expenses recorded in the prior year.
- Derivative Liabilities: Derivative liabilities increased significantly from $208,000 to $870,000 due to the fair value adjustment of warrants issued in connection with a warrant inducement agreement.
- Acquisition: The company acquired Sinaptic Surgical in July 2025, recognizing $302,000 in goodwill and $145,000 in intangible assets.
- Disposition: The company sold its TA&T subsidiary in February 2025 in exchange for the assumption of liabilities, removing associated grant revenues and expenses.
Guidance, Outlook, and Risks
- Strategic Outlook: Management expects revenue from the new SiNAPTIC Foot & Ankle Osteotomy Wedge System to begin in the first half of 2026. The company is also recognizing revenue from a private label agreement for OsseoSculpt starting in Q3 2025.
- Liquidity: The company believes it has sufficient capital to continue as a going concern through at least November 12, 2026. However, it anticipates continued operating losses and will require additional funding for R&D and commercialization.
- Financing Activities: In October 2025, the company entered into a new "At-The-Market" (ATM) offering agreement with an aggregate offering price of approximately $6.4 million. Additionally, a sublease agreement for the former armor facility is expected to save approximately $950,000 over the term.
- Risks: Key risks include the uncertainty of obtaining additional financing on favorable terms, the dilutive nature of future equity raises, and the execution risk of commercializing new medical devices.
Investor Verification Checklist
- Warrant Inducement Impact: Verify the accounting treatment and future dilution impact of the $6.7 million deemed dividend recorded in Q3 2025 related to the warrant inducement.
- Revenue Transition: Monitor the timeline for revenue recognition from the FDA-cleared SiNAPTIC Wedge System (expected H1 2026) to ensure the strategic pivot yields results.
- Cash Burn Rate: Assess the sustainability of the current cash position ($6.25M) against the projected burn rate, given the continued net losses and lack of significant product revenue.
- Derivative Liability Volatility: Track the fair value of derivative liabilities ($870k), as fluctuations in stock price will directly impact reported net income/loss.
- Sublease Execution: Confirm the execution of the sublease for the armor facility to validate the projected $950k cost savings.